Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion.

Future oncology (London, England) 2023 Aug

filter terms:

Neratinib is a tyrosine kinase receptor inhibitor used in the extended adjuvant therapy of early-stage breast cancer. After adjuvant trastuzumab therapy, neratinib reduces the risk of recurrence and, if taken within 1 year from trastuzumab, significantly improves the invasive disease-free survival of patients with early-stage human epidermal growth factor receptor-2 positive (HER2+) breast cancer with no increased risk of long-term toxicity. Diarrhea, the most common adverse event associated with neratinib use, deters some clinicians from prescribing this drug. However, neratinib-related toxicity is predictable, short-lived, mostly limited to the first month of treatment and can be managed with dose-escalation and prophylactic strategies. Thus, close surveillance and prompt management, relying on supportive care and administration schedule modification, allows discontinuation of treatment to be avoided.

Citation

Roberta Caputo, Giuseppe Buono, Vincenzo Di Lauro, Daniela Cianniello, Claudia Von Arx, Matilde Pensabene, Martina Pagliuca, Carmen Pacilio, Francesca Di Rella, Annarita Verrazzo, Claudia Martinelli, Francesco Nuzzo, Michelino De Laurentiis. Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion. Future oncology (London, England). 2023 Aug;19(24):1695-1708